REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the sale, the director now directly owns 11,286 shares of the company’s stock, valued at $114,101.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
REGENXBIO Price Performance
Shares of NASDAQ RGNX traded down $0.29 on Wednesday, hitting $9.92. The company’s stock had a trading volume of 749,278 shares, compared to its average volume of 608,384. The stock has a 50 day moving average of $12.20 and a 200-day moving average of $14.37. The company has a market capitalization of $490.25 million, a price-to-earnings ratio of -1.69 and a beta of 1.22. REGENXBIO Inc. has a 12-month low of $9.90 and a 12-month high of $28.80.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The company had revenue of $22.30 million during the quarter, compared to the consensus estimate of $22.97 million. During the same quarter in the previous year, the firm earned ($1.66) EPS. The company’s revenue was up 11.6% on a year-over-year basis. Sell-side analysts expect that REGENXBIO Inc. will post -4.66 EPS for the current fiscal year.
Institutional Trading of REGENXBIO
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. HC Wainwright reiterated a “buy” rating and set a $39.00 price objective on shares of REGENXBIO in a research note on Wednesday, September 4th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, The Goldman Sachs Group started coverage on shares of REGENXBIO in a report on Friday, June 7th. They set a “buy” rating and a $38.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.91.
Read Our Latest Report on RGNX
About REGENXBIO
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
- Five stocks we like better than REGENXBIO
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- How is Compound Interest Calculated?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- There Are Different Types of Stock To Invest In
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.